Mesoblast Limited
MESO
17.71 $
1 Tag: +7.96% (+1.34 $)
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer MESO
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Aktuelle News
-
Mesoblast Reports Substantial Revenue Growth to US$120M
Vorschau anzeigen
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026). Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very p
-
Mesoblast H2 Earnings Call Highlights
Vorschau anzeigen
Mesoblast (NASDAQ:MESO) reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company’s FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD. Chief Executive Of
-
3 Australian Growth Stocks With Strong Balance Sheets In A Rate Hike Debate
Vorschau anzeigen
Central banks are weighing possible further rate hikes to keep inflation in check, which keeps pressure on weaker balance sheets and slower growth stories. Healthy high growth potential stocks can look more attractive in this kind of rate debate, because markets often pay close attention to future earnings strength and financial resilience. This article highlights three stocks from the screener that meet both tests and explains what sets each apart. The three stocks highlighted below are just...
-
Mesoblast shares jump as Phase 3 chronic back pain trial completes patient treatment
Vorschau anzeigen
Mesoblast Limited (NASDAQ:MESO) shares rose 9. 5% on Monday after the biotechnology company completed patient treatment in a pivotal Phase 3 study evaluating rexlemestrocel-L for chronic low back pain linked to degenerative disc disease.
-
MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up
Vorschau anzeigen
Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.